Cystatin E/M (CST6), a representative cysteine protease inhibitor, has been well appreciated as a tumor-promoting and tumor-suppressing agent and is pursued as an epigenetically therapeutic target in special cancer types (106). This evidence concerns the gene CTSB and neoplasm.